**World Journal of Gastroenterology**

Online Submissions: http://www.wjgnet.com/esps/
bpgoffice@wjgnet.com
doi:10.3748/wjg.v20.i18.5302

**WJG 20th Anniversary Special Issues (6): Helicobacter pylori**

**Helicobacter pylori**: Management in 2013

Yesim Ozen Alahdab, Cem Kalayci

Yesim Ozen Alahdab, Department of Gastroenterology and Hepatology, Fatih Sultan Mehmet Education and Research Hospital, 34752 Istanbul, Turkey
Cem Kalayci, Department of Gastroenterology and Hepatology, Feneryolu Mh Kadikoy, 34724 Istanbul, Turkey

**Author contributions:** Alahdab YO and Kalayci C contributed to this paper equally.

**Correspondence to:** Yesim Ozen Alahdab, MD, Department of Gastroenterology and Hepatology, Fatih Sultan Mehmet Education and Research Hospital, E5 Karayolu Uzeri Icerenkoy-Atasehir, 34752 Istanbul, Turkey. yesimalahdab@yahoo.com
Telephone: +90-532-7230290 Fax: +90-216-5750406
Received: September 30, 2013 Revised: November 25, 2013 Accepted: January 6, 2014 Published online: May 14, 2014

**Abstract**

*Helicobacter pylori* (*H. pylori*) is a prevalent, worldwide, chronic infection. Choice of treatment can be modified according to antibiotic-resistance rates of *H. pylori*. The ideal therapeutic regimen for *H. pylori* infection should achieve an eradication rate of $\geq 80\%$. In some countries, triple therapy with a proton-pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole is still the best option. Bismuth-containing quadruple therapy consisting of bismuth salts, tetracycline, metronidazole and PPI, may be the preferred option in countries with clarithromycin resistance $> 20\%$. Sequential therapy including a PPI and amoxicillin given for the first 5 d, followed by triple therapy including a PPI, clarithromycin, and nitroimidazole antimicrobial (all twice daily) for the remaining 5 d, can be another option for the first-line treatment of *H. pylori*. Recent data suggest that treatment with PPI, levofloxacin, and amoxicillin for 10 d is a good choice for second-line therapy. Concomitant therapy consisting of PPI, amoxicillin, clarithromycin and metronidazole is another option for second-line treatment. If second-line treatment also fails, it is recommended to culture *H. pylori* from biopsy specimens and perform antimicrobial susceptibility testing. Rescue treatment should be based on antimicrobial susceptibility.

**Key words:** Helicobacter pylori; First-line therapy; Second-line therapy; Rescue therapy

**Core tip:** *Helicobacter pylori* (*H. pylori*) is a prevalent, worldwide, chronic infection. The ideal therapy regimen for *H. pylori* infection should achieve an eradication rate $\geq 80\%$. Triple therapy remains an appropriate first-line therapy in areas of low clarithromycin resistance, and quadruple therapy should be the first-line therapy in areas of high clarithromycin resistance. Sequential therapy can be an alternative. Levofloxacin-containing regimens or concomitant therapies can be good choices for second-line therapy. Choice of treatment regimen for *H. pylori* infection should be done cautiously and antibiotic-resistance rates should be taken into consideration.

Alahdab YO, Kalayci C. Helicobacter pylori: Management in 2013. *World J Gastroenterol* 2014; 20(18): 5302-5307 Available from: URL: http://www.wjgnet.com/1007-9327/full/v20/i18/5302.htm DOI: http://dx.doi.org/10.3748/wjg.v20.i18.5302

**INTRODUCTION**

The ideal therapeutic regimen for *Helicobacter pylori* (*H. pylori*) infection should achieve an eradication rate of $\geq 80\%$. Treatment may depend on the patient, treatment indication, local antibiotic-resistance profile, and whether the patient was treated previously for *H. pylori* infection.

**FIRST-LINE THERAPY**

**Triple therapy**

Triple therapy, comprising two antibiotics, amoxicillin and clarithromycin, and a proton pump inhibitor (PPI) for 1 or 2 wk (Table 1), was recommended as the initial...
treatment of choice at several consensus conferences\[^{1,2}\]. Eradication rates with triple therapy range between 70% and 85%\[^{3,6}\]. Most studies support that 1 and 2 wk triple therapy is associated with similar eradication rates\[^{6,7}\]. In contrast, the superiority of 2-wk triple therapy over 1-wk triple therapy has been confirmed by a recent large randomized single center trial from Italy. In an intention-to-treat analysis, 2-wk triple therapy with omeprazole, amoxicillin and clarithromycin achieved a significantly higher eradication rate than 1-wk triple therapy (70% vs 57%, \(P = 0.05\))\[^{8}\]. The most frequently reported side effects include gastrointestinal (GI) upset, diarrhea, and altered taste for clarithromycin, and GI upset, headache, and diarrhea for amoxicillin. However, rates of \(H\). \(P\). \(y\)lori eradication using traditional clarithromycin-containing triple therapies have decreased because of increasing clarithromycin resistance\[^{11}\].

### Quadruple therapy

Triple therapy regimens are becoming less effective, therefore, alternative therapies are needed. Quadruple therapy containing PPI, bismuth, metronidazole and tetracycline given for 10-14 d (Table 1) is a good alternative for first-line treatment of \(H\). \(p\)lori infection\[^{2,10}\]. Success rates range between 75% and 90%. Side effects of metronidazole include a metallic taste in the mouth, dyspepsia, and a disulfiram-like reaction with alcohol consumption. Side effects of tetracycline include GI upset and photosensitivity. Bismuth compounds have been associated with darkening of the tongue and stools, nausea, and GI upset\[^{11}\]. According to the Maastricht III and Maastricht IV Consensus, bismuth-containing quadruple therapy is recommended as first-line therapy, especially in areas with a high prevalence (> 20%) of clarithromycin resistance\[^{12,13}\].

In a meta-analysis comprising 51 trials to 2004, it was reported that quadruple therapy cures > 85% of \(H\). \(p\)lori infections\[^{13}\]. These data were supported by another meta-analysis that reported an eradication rate of 82.6% with bismuth-containing quadruple therapy\[^{13}\].

The success rate of bismuth-containing quadruple therapy is reported as > 90% from different parts of the world\[^{14,15}\]. In a meta-analysis comprising four randomized control trials (RCTs), eradication rates with bismuth-containing quadruple therapy vs clarithromycin-containing triple therapy were reported as 81% \(vs\) 78% (OR = 0.83; 95%CI: 0.61-1.14; \(P = 0.3\))\[^{17}\]. According to these data, quadruple and triple therapies seem to be equivalent in terms of effectiveness, compliance and side-effect profile when administered as first-line treatment for \(H\). \(p\)lori infection. Another meta-analysis reported similar eradication rates for quadruple and triple therapies as first-line therapy for \(H\). \(p\)lori infection. They reported a quadruple-therapy eradication rate of 78.3%, whereas the eradication rate of triple therapy was 77.0% (RR = 1.002, 95%CI: 0.936-1.073)\[^{18}\]. A recent meta-analysis showed that eradication rate of quadruple therapy was 77.6%, whereas triple therapy was 68.9% [risk difference (RD) = 0.06, 95%CI: 0.01-0.13]. In the subgroup analysis of treatment duration, the 10-d quadruple therapy achieved eradication rate of 82.5%, whereas triple therapy achieved an eradication rate of 57.7% (RD = 0.25, 95%CI: 0.18-0.32). Thus, 10-d quadruple therapy was shown to be more effective than the 7-d triple therapy\[^{19}\].

It is surprising that in these reports both therapies yielded overall similar but suboptimal eradication rates, as distinct from the success rate of quadruple therapy trials.

In contrast, there are trials showing that quadruple therapy is better than triple therapy. In a trial consisting of 440 patients, \(H\). \(p\)lori eradication rate of quadruple therapy in intention-to-treat analysis was 80%, whereas eradication rate of triple therapy was 55% (\(P < 0.0001\). \(H\). \(p\)lori eradication rate of quadruple therapy in per-protocol analysis was 93%, whereas eradication rate of triple therapy was 70% (\(P < 0.0001\))\[^{20,21}\]. In another study, the intention-to-treatment eradication rates in quadruple and triple therapies were reported as 89.4% and 63.5%, respectively (\(P < 0.05\). By per protocol analysis, the eradication rates of the two groups were 91.6% and 65.1%, respectively (\(P < 0.05\))\[^{22}\].

### Sequential therapy

The sequential regimen is a simple dual therapy including a PPI plus 1 g amoxicillin (both twice daily) given for the first 5 d, followed by triple therapy including a PPI, 500 mg clarithromycin, and a nitroimidazole antimicrobial (all twice daily) for the remaining 5 d (Table 1). Its initial reported success rate was > 90%\[^{22,23}\]. Initial studies of sequential therapy suggested that its superiority over standard triple therapy might be due to improved eradication of clarithromycin-resistant strains\[^{24,25}\]. In a recent study comparing sequential and triple therapy, \(H\). \(p\)lori eradication rates were 77.8% \(vs\) 62.2%, respectively (\(P = 0.0001\)).

---

**Table 1 Eradication regimens**

| Name of therapy | Time (d) | Contents of therapy |
|-----------------|----------|---------------------|
| Triple therapy  | 7-14     | Proton pump inhibitor (PPI) twice daily + clarithromycin (500 mg twice daily) + amoxicillin (1 g twice daily)  |
| Quadruple therapy | 10-14   | PPI (twice daily) + bismuth subsalicylate (525 mg 4 times daily) + metronidazole (250 mg 4 times daily) + tetracycline (500 mg 4 times daily) |
| Levofoxacin therapy | 7-10   | PPI (twice daily) + levofloxacin (250 mg twice daily) + amoxicillin (1 g twice daily) |
| Sequential therapy | 10      | PPI (twice daily) + amoxicillin (1 g twice daily) for the first 5 d followed by PPI + clarithromycin (500 mg twice daily) + metronidazole/tinidazole |
| Concomitant therapy | 10     | PPI (twice daily) + amoxicillin (1 g twice daily) + clarithromycin (500 mg twice daily) + metronidazole |
| Levofoxacin-containing sequential therapy | 10    | PPI + amoxicillin (1 g twice daily) for the first 5 d followed by PPI + levofloxacin (500 mg daily) + metronidazole |

---

\[\text{Table 1 Eradication regimens}\]

\[\text{WJG} \mid \text{www.wjgnet.com}\]

May 14, 2014 \| Volume 20 \| Issue 18 \|
In this study, the reported eradication rate of sequential therapy was lower than in previous studies. In a multicenter study from Latin America comprising 1463 patients, sequential therapy was not significantly better than standard triple therapy. Eradication rates were 82.2% vs 76.5% for triple and sequential therapy, respectively. In another meta-analysis, the overall eradication rate of sequential therapy was reported to be 84.3%, and it was not superior to 14-d triple therapy, bismuth-containing quadruple therapy, and non-bismuth quadruple therapy.

It has been suggested that levofloxacin rather than clarithromycin can achieve better eradication rates in sequential regimes. Eradication rates of levofloxacin containing sequential therapy were reported as 95.1% and 90% from Taiwan and Turkey, respectively.

**SECOND-LINE THERAPIES**

In patients who were treated for *H. pylori* infection, and did not achieve eradication, second-line therapy is required. The Maastricht IV consensus states that if triple therapy fails, either a bismuth-containing quadruple therapy or levofloxacin-containing triple therapy can be used as second-line therapy.

Levofloxacin-containing therapy can be used as second-line therapy in case of triple-therapy failure or as second-line therapy in case of failure of bismuth-containing quadruple therapy in areas of high clarithromycin resistance. In this case, levofloxacin-containing triple therapy consists of PPI, levofloxacin, and amoxicillin and is used for 10 d (Table 1). Side effects of levofloxacin consist of anorexia, nausea, vomiting and abdominal discomfort. It may also cause mild headache and dizziness.

In two different meta-analyses it has been shown that levofloxacin therapy was superior to quadruple therapy as second-line treatment of *H. pylori* infection. Meta-analysis also showed that levofloxacin-containing triple therapy has fewer adverse effects and is better tolerated than quadruple-therapy regimens. After *H. pylori* eradication failure, levofloxacin triple therapy is more effective and better tolerated than bismuth-containing quadruple therapy.

In spite of these results, levofloxacin therapy should be used cautiously because of rising rates of levofloxacin resistance.

Levofloxacin therapy can also be good as an alternative after failure of non-bismuth-containing quadruple sequential or concomitant treatment to eradicate *H. pylori* infection.

Classical concomitant or non-bismuth-based quadruple therapy consists of PPI, amoxicillin, clarithromycin, and metronidazole. Eradication rates of 94.9% and 91.4% were obtained with non-bismuth-containing quadruple therapy in studies from Japan and Greece, respectively. A meta-analysis comprising 19 studies (2070 patients) revealed a mean *H. pylori* eradication rate of 88% for non-bismuth-containing quadruple therapy. In this meta-analysis, it has been shown that concomitant therapy was more effective than triple therapy with an eradication rate of 90% vs 78%, respectively.

**RESCUE THERAPY**

Rifabutin-based rescue therapy constitutes an encouraging strategy after previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin. Rifabutin can be an alternative to bismuth-based quadruple salvage therapy. In trials using rifabutin-based therapy, eradication rates are reported at > 80%. Side effects of rifabutin include rash and GI upset such as nausea, vomiting, dyspepsia and diarrhea, and red discoloration of urine. Rarely, rifabutin is associated with myelotoxicity and ocular toxicity.

If second-line therapy also fails, it is recommended to culture *H. pylori* from biopsy specimens and perform antimicrobial susceptibility testing.

**PENICILLIN ALLERGIC PATIENTS**

PPI, clarithromycin and metronidazole therapy can be first-line treatment for the patients with penicillin allergy living in areas of low clarithromycin resistance. PPI, tetracycline and metronidazole regimens or bismuth-containing quadruple therapy can be used in areas of high clarithromycin resistance. As an alternative treatment PPI, bismuth subcitrate, rifabutin and ciprofloxacin are used for patients with penicillin allergy and this therapy gave an eradication rate of 94.2%.

**EXPERIMENTAL TREATMENTS**

There is some evidence that adding 500 mg vitamin C plus 200 U vitamin E twice daily for 30 d may increase *H. pylori* eradication rate. Similarly, adding bovine lactoferrin to *H. pylori* eradication therapy potentially improves *H. pylori* eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings.

In a study from Turkey, it has been shown that Saccharomyces boulardii had no significant effect on the rate of *H. pylori* eradication. In contrast, *S. boulardii* improved antibiotic-therapy-associated diarrhea, epigastric discomfort, and treatment tolerability. However, systematic review of five RCTs evaluating addition of *S. boulardii* to triple therapy showed that *S. boulardii* given along with triple therapy significantly increased the eradication rate (4 RCTs, *n* = 915, RR = 1.13, 95%CI: 1.05-1.21) and reduced the risk of overall *H. pylori* therapy-related adverse effects, particularly of diarrhea (4 RCTs, *n* = 1215, RR = 0.47, 95%CI: 0.32-0.69).

**OTHER FACTORS**

There are some factors affecting eradication success. Cytochrome P450 2C19 (CYP2C19) and P-glycoprotein (MDR1) gene polymorphisms, which influence the clear-
ance of PPIs, and thus their effect on gastric acid secretion, may affect the therapeutic efficacy of a PPI-based eradication therapy for *H. pylori* infection[54]. In particular, T/T genotype of the MDR1 C3435T polymorphism could be a predictive indicator of the lower eradication rate of a PPI-based eradication therapy[55]. The usage of high-dose PPI instead of standard dose can increase the efficacy of treatment. According to a meta-analysis, high-dose PPI is more effective than standard dose, and increases eradication rate by approximately 8%[56].

Smoking decreases the treatment success rate for *H. pylori* eradication. In a meta-analysis consisting of 22 published studies, it has been reported that the mean difference in eradication rates between smokers and non-smokers was 8.4%[57].

**CONCLUSION**

Triple therapy remains an appropriate first-line therapy in areas of low clarithromycin resistance; conversely, quadruple therapy should be the first-line therapy in areas of high clarithromycin resistance. The usage of sequential therapy has become increasingly common, however, more data are needed before recommending sequential therapy as first-line therapy. Levofloxacin-containing regimens or concomitant therapies can be good choices for second-line therapy; Choice of treatment regimen of *H. pylori* should be done cautiously and resistance rates of antibiotics should be taken into consideration.

**REFERENCES**

1. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; 56: 772-781 [PMID: 1710018]

2. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; 102: 1808-1825 [PMID: 17608775]

3. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. *Aliment Pharmacol Ther* 2011; 34: 1255-1268 [PMID: 22017749 DOI: 10.1111/j.1365-2036.2011.04887.x]

4. Fujioka T, Aoyama N, Sakai K, Miwa Y, Kudo M, Kawashima J, Matsubara Y, Miwa J, Yakabi K. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan. *J Gastroenterol* 2012; 47: 276-283 [PMID: 22065160 DOI: 10.1007/s00535-011-0487-4]

5. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. *Gastroenterology* 2002; 123: 1763-1769 [PMID: 12458831]

6. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori infection. *Ann Intern Med* 2007; 147: 553-562 [PMID: 17938394]

7. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. *Gut* 2007; 56: 475-479 [PMID: 17028126]

8. Paoluzi P, Iacopini P, Crispino P, Nardi F, Bella A, Rivera M, Rossi P, Gamari M, Canacciolo F, Zippini P, Pica R. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. *Helicobacter* 2006; 11: 562-568 [PMID: 17083378]

9. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. *Drugs* 2008; 68: 725-736 [PMID: 18416582]

10. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

11. Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. *Hosp Pract* (1995) 2011; 39: 133-140 [PMID: 21441768 DOI: 10.3810/hp.2011.02.305]

12. Fischbach LA, Van Zanten S, Dickson J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. *Aliment Pharmacol Ther* 2004; 20: 1071-1082 [PMID: 15569109]

13. Buzas GM, Józán J. First-line eradication of *H pylori* infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. *World J Gastroenterol* 2006; 12: 5311-5319 [PMID: 16981260]

14. Ergüli B, Doğan Z, Sarikaya M, Filik L. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. *Helicobacter* 2013; 18: 454-458 [PMID: 24011287 DOI: 10.1111/hel.12086]

15. Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. *Eur J Gastroenterol Hepatol* 2013; 25: 1134-1140 [PMID: 23778309]

16. Dore MP, Farina V, Cucco M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. *Helicobacter* 2011; 16: 295-300 [PMID: 21762269 DOI: 10.1111/j.1523-5378.2011.00857.x]

17. Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. *Aliment Pharmacol Ther* 2003; 17: 1137-1143 [PMID: 12752590]

18. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol* 2010; 105: 65-73 [PMID: 19755966 DOI: 10.1038/ajg.2009.508]

19. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. *Digestion* 2013; 88: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]

20. Malfertheiner P, Bazzoli F, Delcher JC, Celitiški K, Giguère M, Rivière M, Megraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; 377: 905-913 [PMID: 21435487 DOI: 10.1016/S0140-6736(11)60202-2]

21. Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. *J Dig Dis* 2010; 11: 313-318 [PMID: 20883428 DOI: 10.1111/j.1751-2980.2010.00457.x]

22. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Berna-
bucco V, Cavana M, Lerardi E, Morini S, Vaira D. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. *Aliment Pharmacol Ther* 2005; 21: 1419-1424 [PMID: 15948888].

23 Scaccianoce G, Hassan C, Panarise A, Pigliomico D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. *Can J Gastroenterol* 2006; 20: 113-117 [PMID: 16482238].

24 Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, Rinaldi V, Perri F, Papadia C, Fornari F, Filati S, Mete LS, Merla A, Poti R, Marinone G, Savioli A, Campo SM, Falco D, Lerardi E, Miglioli M, Morini S. High eradication rates of Helicobacter pylori with a new sequential treatment. *Aliment Pharmacol Ther* 2003; 17: 719-726 [PMID: 12641522].

25 Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. *Ann Intern Med* 2007; 146: 556-563 [PMID: 17438314].

26 Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, Park KS, Lee SH, Kim KO, Jeon SW. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naive patients. *Aliment Pharmacol Ther* 2012; 35: 56-65 [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x].

27 Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo TJ, Dominitz J, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, Wang WM, Wu DC. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. *J Clin Gastroenterol* 2011; 45: 652-656 [PMID: 23556551 DOI: 10.3109/00365521.2013.761132].

28 Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013; 347: f4857 [PMID: 23926315 DOI: 10.1136/bmj.f4857].

29 Liu JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. *J Antimicrob Chemother* 2011; 66: 1847-1852 [PMID: 21632579 DOI: 10.1093/jac/dkr217].

30 Polat Z, Kadayifici A, Kantarcigloo M, Ozcan A, Emer O, Uygun A. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori. *Eur J Intern Med* 2012; 23: 165-168 [PMID: 22284248 DOI: 10.1016/j.ejim.2011.02.011].

31 Gisbert JP, Pérez-Aisa A, Bermejo F, Castro-Fernández M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernández-Bermejo M, Rodrigo L, Castro J, physg, Almagro P, Fester V, Clemente R, Villani MR, Quittadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. *Am J Gastroenterol* 2001; 96: 58-62 [PMID: 11197288].

32 Bock H, Koop H, Lehn N, Heep M. Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience. *J Clin Gastroenterol* 2000; 31: 222-225 [PMID: 11034001].

33 Bordoy TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Sureau R, Llorente R, Ng C. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. *Aliment Pharmacol Ther* 2006; 23: 481-488 [PMID: 16441468].

34 Cammarata G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, Cazzato A, Cannizzaro O, Miele L, Grieco A, Gasbarrini A, Gasbarrini G. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. *Aliment Pharmacol Ther* 2004; 19: 789-795 [PMID: 15043520].

35 Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. *Aliment Pharmacol Ther* 2005; 22: 1041-1046 [PMID: 16269980].
46 Rodríguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, Aponte-Rivera E, Marxuach-Cuéntara AM, Rodríguez-Orengo JF, Marshall-Carbajal A. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 2005; 50: 634-639 [PMID: 15844694]

47 Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 2012; 36: 1076-1083 [PMID: 23072648 DOI: 10.1111/apt.12089]

48 Sezikli M, Çetinkaya ZA, Güzelbulut F, Yeşil A, Cosgun S, Kurdaş OO. Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori. J Clin Pharm Ther 2012; 37: 282-285 [PMID: 21740452 DOI: 10.1111/j.1365-2710.2011.01286.x]

49 Sezikli M, Cetinkaya ZA, Sezikli H, Güzelbulut F, Tiftikçi A, Ince AT, Gökden Y, Yaşar B, Atalay S, Kurdaş OO. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? Helicobacter 2009; 14: 280-285 [PMID: 19674132 DOI: 10.1111/j.1523-5378.2009.00686.x]

50 Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009; 29: 720-730 [PMID: 19183156 DOI: 10.1111/j.1365-2133.2009.03934.x]

51 Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309-316 [PMID: 17669103]

52 Duman DG, Bor S, Özütemiz O, Sahin T, Öğuz D, İştan F, Vural T, Sandikci M, İşkal F, Simsak I, Soytürk M, Arslan S, Sivri B, Soykan I, Temizkan A, Beşik F, Kaymakoğlu S, Kalayç C. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17: 1357-1361 [PMID: 16292090]

53 Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]

54 Gawrońska-Szlizarz B, Wrześniowska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 2005; 61: 375-379 [PMID: 15976989]

55 Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. Aliment Pharmacol Ther 2007; 26: 693-703 [PMID: 17697203]

56 Villoria A, García P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868-877 [PMID: 18644011 DOI: 10.1111/j.1365-2036.2008.03807.x]

57 Suzuki T, Matsu K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R, Tajima K. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-224 [PMID: 16490464]
